Update in diffuse parenchymal lung disease 2011

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 1, 2012, Pages 24-29

  Luckhardt, Tracy R ^a   Müller Quernheim, Joachim ^b   Thannickal, Victor J ^a  

^a and Clinical Center   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BOSENTAN; GAMMA INTERFERON; NINTEDANIB; PIRFENIDONE; PLACEBO; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; WARFARIN;

ALLERGIC PNEUMONITIS; AUTOIMMUNITY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE DISEASE; DIFFUSE PARENCHYMAL LUNG DISEASE; FIBROBLAST; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION; LUNG DISEASE; MEDICAL SOCIETY; NONHUMAN; OCCUPATIONAL LUNG DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK; SARCOIDOSIS;

ALVEOLITIS, EXTRINSIC ALLERGIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTOIMMUNITY; CLINICAL TRIALS AS TOPIC; COMORBIDITY; GASTROESOPHAGEAL REFLUX; HOMEOSTASIS; HUMANS; LUNG DISEASES, INTERSTITIAL; PYRIDONES; RISK ASSESSMENT; SARCOIDOSIS, PULMONARY;

EID: 84863451748     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201203-0509UP     Document Type: Review

References (61)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-664.
3. Schunemann HJ, Jaeschke R, Cook DJ, Bria WF, El-Solh AA, Ernst A, Fahy BF, Gould MK, Horan KL, Krishnan JA, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006;174:605-614. (Pubitemid 44330555)
4. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183: 431-440.
5. Noble PW, Richeldi L, Kaminski N. End of an era: lessons from negative clinical trials in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:4-5.
6. King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:92-99.
7. IPFnet. ACE-IPF. December 9, 2011 [accessed 2012 Apr 25]. Available from: https://www.ipfnet.org/clinical-trials/.
8. Garneau-Tsodikova S, Thannickal VJ. Protein kinase inhibitors in the treatment of pulmonary fibrosis. Curr Med Chem 2008;15:2632-2640.
9. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-1087.
10. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63:v1-v58.
11. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229-2242. (Pubitemid 41697286)
12. NHLBI. Commonly used three-drug regimen for idiopathic pulmonary fibrosis found harmful. October 21, 2011 [accessed 2012 March 7]. Available from: http://www.nih.gov/news/health/oct2011/nhlbi-21.htm.
13. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (capacity): two randomised trials. Lancet 2011;377:1760-1769.
14. Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, Richeldi L. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010;CD003134.
15. Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sato A, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011;12:143.
16. Bouros D. Pirfenidone for idiopathic pulmonary fibrosis. Lancet 2011; 377:1727-1729.
17. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-415. (Pubitemid 20025670)
18. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184:1382-1389.
19. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011;183:1231-1237.
20. Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, Hansell DM, du Bois RM, Wells AU. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:830-836.
21. Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sato A, et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 2011;12:93.
22. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374:222-228.
23. Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, Brown KK. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010;65:173-177.
24. Raghu G, King TE Jr, Behr J, Brown KK, du Bois RM, Leconte I, Roux S, Swigris J. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010;35:118-123.
25. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012;185:1044-1048.
26. du Bois RM,Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:459-466.
27. Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, Lederer DJ. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011;184:842-847.
28. Chung CR, Park SJ, Min KH, Kim SR, Lee MH, Han HJ, Choi KH, Jin GY, Chung MJ, Lee YC. An unusual localized progressive fibrotic cavity mimicking lung malignancy in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:140.
29. Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006;129:794-800.
30. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE Jr, Collard HR. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:1390-1394.
31. Wootton SC, Kim DS, Kondoh Y, Chen E, Lee JS, Song JW, Huh JW, Taniguchi H, Chiu C, Boushey H, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:1698-1702.
32. Kolb MR, Richeldi L. Viruses and acute exacerbations of idiopathic pulmonary fibrosis: rest in peace? Am J Respir Crit Care Med 2011; 183:1583-1584.
33. Pulkkinen V, Salmenkivi K, Kinnula VL, Sutinen E, Halme M, Hodgson U, Lehto J, Jaaskelainen A, Piiparinen H, Kere J, et al. A novel screening method detects herpesviral DNA in the idiopathic pulmonary fibrosis lung. Ann Med 2012;44:178-186.
34. Lawson WE, Cheng DS, Degryse AL, Tanjore H, Polosukhin VV, Xu XC, Newcomb DC, Jones BR, Roldan J, Lane KB, et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci USA 2011;108:10562-10567.
35. Lawson WE, Crossno PF, Polosukhin VV, Roldan J, Cheng DS, Lane KB, Blackwell TR, Xu C, Markin C, Ware LB, et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol 2008;294:L1119-L1126.
36. Taille C, Grootenboer-Mignot S, Boursier C, Michel L, Debray MP, Fagart J, Barrientos L, Mailleux A, Cigna N, Tubach F, et al. Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:759-766.
37. Feghali-Bostwick CA, Wilkes DS. Autoimmunity in idiopathic pulmonary fibrosis: are circulating autoantibodies pathogenic or epiphenomena? Am J Respir Crit Care Med 2011;183:692-693.
38. Gibbons MA, MacKinnon AC, Ramachandran P, Dhaliwal K, Duffin R, Phythian-Adams AT, van Rooijen N, Haslett C, Howie SE, Simpson AJ, et al. Ly6chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med 2011;184:569-581.
39. Lo Re S, Lecocq M, Uwambayinema F, Yakoub Y, Delos M, Demoulin JB, Lucas S, Sparwasser T, Renauld JC, Lison D, et al. Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis. Am J Respir Crit Care Med 2011;184:1270-1281.
40. Atamas SP, Fontenot AP. Regulatory T cells and lung fibrosis: a good cell gone bad. Am J Respir Crit Care Med 2011;184:1224-1226.
41. Atochina-Vasserman EN, Bates SR, Zhang P, Abramova H, Zhang Z, Gonzales L, Tao JQ, Gochuico BR, Gahl W, Guo CJ, et al. Early alveolar epithelial dysfunction promotes lung inflammation in a mouse model of Hermansky-Pudlak syndrome. Am J Respir Crit Care Med 2011;184:449-458.
42. Perl AK, Riethmacher D, Whitsett JA. Conditional depletion of airway progenitor cells induces peribronchiolar fibrosis. Am J Respir Crit Care Med 2011;183:511-521.
43. Wygrecka M, Kwapiszewska G, Jablonska E, von Gerlach S, Henneke I, Zakrzewicz D, Guenther A, Preissner KT, Markart P. Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:1703-1714.
44. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378:1949-1961.
45. Hoyles RK, Derrett-Smith EC, Khan K, Shiwen X, Howat SL, Wells AU, Abraham DJ, Denton CP. An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor beta receptor. Am J Respir Crit Care Med 2011;183:249-261.
46. Lin X, Sime PJ, Xu H, Williams MA, LaRussa L, Georas SN, Guo J. Yin yang 1 is a novel regulator of pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:1689-1697.
47. Olsen KC, Sapinoro RE, Kottmann RM, Kulkarni AA, Iismaa SE, Johnson GV, Thatcher TH, Phipps RP, Sime PJ. Transglutaminase 2 and its role in pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:699-707.
48. Lawson WE, Blackwell TS, Gauldie J. Let it be: microRNAs impact interstitial lung disease. Am J Respir Crit Care Med 2011;183:1-2.
49. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011;183:573-581.
50. Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger D, Brown KK. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med 2011;183:1524-1530.
51. Rastogi R, Du W, Ju D, Pirockinaite G, Liu Y, Nunez G, Samavati L. Dysregulation of p38 and MKP-1 in response to NOD1/TLR4 stimulation in sarcoid bronchoalveolar cells. Am J Respir Crit Care Med 2011;183:500-510.
52. Chen ES, White ES. Innate pathways shape sarcoidosis signaling: from bugs to drugs. Am J Respir Crit Care Med 2011;183:425-427.
53. Fischer A, Nothnagel M, Franke A, Jacobs G, Saadati HR, Gaede KI, Rosenstiel P, Schurmann M, Muller-Quernheim J, Schreiber S, et al. Association of inflammatory bowel disease risk loci with sarcoidosis, and its acute and chronic subphenotypes. Eur Respir J 2011;37:610-616.
54. Fischer A, Nothnagel M, Schurmann M, Muller-Quernheim J, Schreiber S, Hofmann S. A genome-wide linkage analysis in 181 German sarcoidosis families using clustered biallelic markers. Chest 2010;138:151-157.
55. Hofmann S, Fischer A, Till A, Muller-Quernheim J, Hasler R, Franke A, Gade KI, Schaarschmidt H, Rosenstiel P, Nebel A, et al. A genomewide association study reveals evidence of association with sarcoidosis at 6p12.1. Eur Respir J 2011;38:1127-1135.
56. Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, et al. Toward the bloodborne miRNome of human diseases. Nat Methods 2011;8:841-843.
57. Koth LL, Solberg OD, Peng JC, Bhakta NR, Nguyen CP, Woodruff PG. Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am J Respir Crit Care Med 2011;184:1153-1163.
58. Blanchet MR, Bennett JL, Gold MJ, Levantini E, Tenen DG, Girard M, Cormier Y, McNagny KM. CD34 is required for dendritic cell trafficking and pathology in murine hypersensitivity pneumonitis. Am J Respir Crit Care Med 2011;184:687-698.
59. Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, Murphy J, Cohen M, Raghu G, Brown KK. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011;183:372-378.
60. Paris C, Pairon JC, Billon-Galland MA, Vanoni-Espiand H, Godbert B, Martinet Y, Chabot F, Aymard B, Vignaud JM. Giant cell interstitial pneumonia: report of two cases with high titanium concentration in the lung. Am J Respir Crit Care Med 2011;184:1315-1317.
61. Bayram H, Ghio AJ. Killer jeans and silicosis. Am J Respir Crit Care Med 2011;184:1322-1324.